WIL Research Acquires Ricerca’s Pharma Service Business in Lyon, France - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

WIL Research Acquires Ricerca’s Pharma Service Business in Lyon, France
The move doubles the CRO’s capacity in Europe.


The CRO WIL Research has acquired Ricerca Biosciences’ pharmaceutical services business located in Lyon, France. The addition of the 18,000-m2 facility strengthens WIL Research’s service offerings in Europe, adds to its nonclinical safety assessment capability, and expands its portfolio of specialty services. The acquisition doubles WIL’s capacity in Europe, according to a WIL press release.

Renamed WIL Research Europe–Lyon, the laboratory will retain its approximately 280 employees. Long-time Managing Director of the facility, Stéphane Bulle, will continue to lead the site and keep his current senior leadership team intact, according to the WIL statement.

The Lyon facility provides safety pharmacology and specialized services, including continuous infusion and developmental and reproductive toxicology. WIL Research now has approximately 1200 staff worldwide and 63,000 m2 of laboratory space in the US, The Netherlands, and now Lyon, France. It also maintains commercial representation in Asia.

For Ricerca, the divestiture provides further funding for its Ohio operations. “This divestiture will fund significant capital investment into our Concord, Ohio business allowing us to expand and re-invigorate our integrated drug development services in chemical development, drug substance production, and drug safety and metabolism,” commented Michael Placke, president of Ricerca Biosciences, in the WIL statement.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here